{"nctId":"NCT00791492","briefTitle":"An Extension of Study Fx-005 Evaluating Long-Term Safety And Clinical Outcomes Of Fx-1006A In Patients With Transthyretin Amyloid Polyneuropathy","startDateStruct":{"date":"2008-07"},"conditions":["Familial Amyloid Polyneuropathy","ATTR-PN"],"count":86,"armGroups":[{"label":"Fx-1006A","type":"EXPERIMENTAL","interventionNames":["Drug: Fx-1006A"]}],"interventions":[{"name":"Fx-1006A","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nMale and non-pregnant female patients meeting all of the following criteria are eligible for enrollment in this study:\n\n* Patient has completed the Month 18 visit of Study Fx-005.\n* If female, patient is post-menopausal, surgically sterilized, or willing to use an acceptable method of birth control (i.e., a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom with spermicide) throughout the study. (A condom alone is not considered an acceptable method of birth control.) If male with a female partner of childbearing potential, willing to use an acceptable method of birth control for the duration of the study. For both females and males, acceptable birth control must be used for at least 3 months after the last dose of study medication.\n* Patient is, in the opinion of the investigator, willing and able to comply with the study medication regimen and all other study requirements.\n* Patient agrees not to participate in another investigational drug or device study while participating in this open-label extension study.\n\nExclusion Criteria:\n\nPatients meeting any of the exclusion criteria will not be enrolled in the study:\n\n* Chronic use of non-steroidal anti-inflammatory drugs (NSAIDs), defined as greater than 3-4 times/month (ibuprofen and nimesulide will be permitted).\n* If female, patient is pregnant or breast feeding.\n* Patient has liver function test abnormalities: alanine transaminases (ALT) and/or aspartate transaminases (AST) \\>2 times upper limit of normal (ULN) that in the medical judgment of the investigator are due to reduced liver function or active liver disease.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Response to Treatment as Measured by Neuropathy Impairment Score - Lower Limb (NIS-LL) at Month 6","description":"Response to treatment indicated by either improvement(decrease from baseline) or stabilization(change from baseline of 0 to less than\\[\\<\\] 2) in NIS-LL score,based on mean of 2 scores in 1 week period.NIS-LL assessed muscle weakness,reflexes,sensation.Each item scored separately for left,right limbs.Components of muscle weakness:0(normal)-4(paralysis),higher score=more weakness;reflexes,sensation:0=normal,1=decreased,or 2=absent.Total NIS-LL score range 0-88,higher score=more impairment. For tafamidis-tafamidis group, NIS-LL baseline value of previous study FX-005(NCT00409175) used as reference.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"62.2","spread":null},{"groupId":"OG001","value":"68.8","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Response to Treatment as Measured by Neuropathy Impairment Score - Lower Limb (NIS-LL) at Month 12","description":"Response to treatment indicated by either improvement(decrease from baseline) or stabilization(change from baseline of 0 to less than\\[\\<\\] 2) in NIS-LL score,based on mean of 2 scores in 1 week period.NIS-LL assessed muscle weakness,reflexes,sensation.Each item scored separately for left,right limbs.Components of muscle weakness:0(normal)-4(paralysis),higher score=more weakness;reflexes,sensation:0=normal,1=decreased,or 2=absent.Total NIS-LL score range 0-88,higher score=more impairment. For tafamidis-tafamidis group, NIS-LL baseline value of previous study FX-005(NCT00409175) used as reference.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"54.5","spread":null},{"groupId":"OG001","value":"60.0","spread":null}]}]}]},{"type":"PRIMARY","title":"Change From Baseline in Norfolk Quality of Life- Diabetic Neuropathy (QOL-DN) Total Quality of Life (TQOL) Score at Month 6","description":"Norfolk QOL-DN: 35-item participant-rated questionnaire used to assess impact of diabetic neuropathy on the quality of life of participants with diabetic neuropathy; Item 1 to 7: related to symptoms and presence of symptoms was assessed as 1 and absence was assessed as 0. Item 8-35: related to activities of daily living and scored on a 5-point Likert scale, where 0= no problem and 4= severe problem (except item 32, where -2= much better, 0=about the same, 2=much worse). TQOL= sum of all the items, total possible score range= -2 to 138, where higher score=worse quality of life.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21.05","spread":"21.88"},{"groupId":"OG001","value":"38.09","spread":"31.89"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.03","spread":"8.83"},{"groupId":"OG001","value":"-4.88","spread":"15.29"}]}]}]},{"type":"PRIMARY","title":"Change From Baseline in Norfolk Quality of Life- Diabetic Neuropathy (QOL-DN) Total Quality of Life (TQOL) Score at Month 12","description":"Norfolk QOL-DN: 35-item participant-rated questionnaire used to assess impact of diabetic neuropathy on the quality of life of participants with diabetic neuropathy; Item 1 to 7: related to symptoms and presence of symptoms was assessed as 1 and absence was assessed as 0. Item 8-35: related to activities of daily living and scored on a 5-point Likert scale, where 0= no problem and 4= severe problem (except item 32, where -2= much better, 0=about the same, 2=much worse). TQOL= sum of all the items, total possible score range= -2 to 138, where higher score=worse quality of life.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.25","spread":"8.91"},{"groupId":"OG001","value":"-2.33","spread":"15.66"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Neuropathy Impairment Score - Lower Limb (NIS-LL) Score at Month 6 and 12","description":"NIS-LL: assessed muscle weakness, reflexes and sensation; scored separately for left and right limbs. Components of muscle weakness (hip and knee flexion, hip and knee extension, ankle dorsiflexors, ankle plantar flexors, toe extensors, toe flexors) are scored on scale 0 (normal) to 4 (paralysis), higher score=greater weakness. Components of reflexes (quadriceps femoris, triceps surae) and sensation (touch pressure, pin-prick, vibration, joint position) were scored 0 = normal, 1= decreased, or 2 = absent. Total possible NIS-LL score range 0-88, higher score=greater impairment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.38","spread":"13.23"},{"groupId":"OG001","value":"17.50","spread":"20.82"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.93","spread":"3.65"},{"groupId":"OG001","value":"1.89","spread":"4.55"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.36","spread":"4.77"},{"groupId":"OG001","value":"1.60","spread":"8.20"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Norfolk Quality of Life - Diabetic Neuropathy (QOL-DN) Domain Scores at Month 6 and 12","description":"Norfolk QOL-DN: 35-item participant-rated questionnaire to assess impact of DN on QOL; Item 1-7:scored as 1=symptoms present, 0=symptoms absent. Item 8-35:scored on 5-point Likert scale: 0=no problem,4=severe problem (except item 32: -2=much better, 0=about same, 2=much worse). Norfolk QOL-DN summarized in 5 domains(score range):physical functioning/large fiber neuropathy(-2 to 58), activities of daily living(ADLs) (0 to 20), symptoms(0 to 32), small fiber neuropathy(0 to 16), autonomic neuropathy(0 to 12); higher score=greater impairment,for each. Total score=-2 to138(higher score=worse QOL).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.45","spread":"11.43"},{"groupId":"OG001","value":"19.88","spread":"17.44"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.21","spread":"4.38"},{"groupId":"OG001","value":"3.48","spread":"5.13"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.34","spread":"4.43"},{"groupId":"OG001","value":"7.48","spread":"5.48"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.50","spread":"3.85"},{"groupId":"OG001","value":"4.42","spread":"4.23"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.55","spread":"2.37"},{"groupId":"OG001","value":"2.82","spread":"3.12"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.14","spread":"4.08"},{"groupId":"OG001","value":"-3.00","spread":"8.08"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.30","spread":"1.45"},{"groupId":"OG001","value":"-0.59","spread":"3.02"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"3.18"},{"groupId":"OG001","value":"-0.75","spread":"4.27"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.14","spread":"2.64"},{"groupId":"OG001","value":"-0.09","spread":"2.32"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.19","spread":"1.33"},{"groupId":"OG001","value":"-0.44","spread":"2.00"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.84","spread":"6.00"},{"groupId":"OG001","value":"-0.83","spread":"9.62"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.13","spread":"1.01"},{"groupId":"OG001","value":"-0.50","spread":"3.35"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.66","spread":"2.54"},{"groupId":"OG001","value":"-1.10","spread":"3.32"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.41","spread":"2.87"},{"groupId":"OG001","value":"0.40","spread":"2.61"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.53","spread":"1.46"},{"groupId":"OG001","value":"-0.30","spread":"1.66"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Summated 7 Score for Large Nerve Fiber Function at Month 6 and 12","description":"Summated 7 score: composite score included five Nerve Conduction Studies (NCS) attributes (peroneal nerve distal motor latency, peroneal nerve compound muscle action potential, peroneal nerve motor conduction velocity, tibial nerve distal motor latency, and sural nerve sensory nerve action potential amplitude) along with Vibration Detection Threshold (VDT) obtained in great toes, and Heart Rate Response to Deep Breathing (HRDB) value. Score was determined through reference to normal values for age, sex and height. Total score range= -26 to 26, where higher score=worse nerve function.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.68","spread":"8.51"},{"groupId":"OG001","value":"10.06","spread":"10.68"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.01","spread":"2.99"},{"groupId":"OG001","value":"1.38","spread":"3.58"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.64","spread":"3.23"},{"groupId":"OG001","value":"1.48","spread":"4.02"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Summated 3 Score for Small Nerve Fiber Function at Month 6 and 12","description":"Summated 3 Nerve Tests Small Fiber Normal Deviates Score (NTSFnds) included cooling threshold for the lower limbs, heat pain threshold for the lower limbs and HRDB. Total score range= -11.2 to 11.2, where higher score=worse nerve function.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.78","spread":"4.33"},{"groupId":"OG001","value":"7.08","spread":"4.39"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.43","spread":"1.51"},{"groupId":"OG001","value":"0.38","spread":"1.08"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.59","spread":"1.28"},{"groupId":"OG001","value":"0.50","spread":"1.48"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Modified Body Mass Index (mBMI) at Month 6 and 12","description":"BMI was calculated by weight divided by height squared. mBMI was calculated by multiplying BMI by serum albumin levels to compensate for edema formation. A progressive decline in mBMI indicated worsening of disease severity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.94","spread":"2.97"},{"groupId":"OG001","value":"22.71","spread":"5.15"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.13","spread":"0.81"},{"groupId":"OG001","value":"0.42","spread":"1.14"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.12","spread":"1.16"},{"groupId":"OG001","value":"0.73","spread":"1.45"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Troponin I Concentration at Week 6, Month 3, 6 and 12","description":"Troponin I was biomarker of cardiac stress (myocardial necrosis and increased filling pressures/ left ventricular \\[LV\\] wall stress).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":null},{"groupId":"OG001","value":"0.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in N-Terminal Prohormone Brain Natriuretic Peptide (NT-proBNP) Concentration at Week 6, Month 3, 6 and 12","description":"NT-proBNP was biomarker of cardiac stress (myocardial necrosis and increased filling pressures/ LV wall stress).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41.0","spread":null},{"groupId":"OG001","value":"75.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.0","spread":null},{"groupId":"OG001","value":"-1.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.0","spread":null},{"groupId":"OG001","value":"1.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.0","spread":null},{"groupId":"OG001","value":"-6.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Intraepidermal Nerve Fiber (IENF) Density","description":"IENF density was quantified in 3 millimeter (mm) immunostained skin punch biopsies containing epidermis and superficial dermis to evaluate the amount and morphological appearance of small diameter nerve fibers, both somatic and autonomic, in sensory neuropathies. It is used in diagnosing various neuropathic conditions.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.2","spread":"9.8"},{"groupId":"OG001","value":"8.0","spread":"9.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.1","spread":"12.6"},{"groupId":"OG001","value":"15.3","spread":"11.9"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Stabilized Transthyretin (TTR) Tetramer","description":"TTR tetramer was assessed using a validated immunoturbidimetric assay. The Fraction of Initial (FOI) is the ratio of the measured TTR tetramer concentration after denaturation to the measured TTR tetramer concentration before denaturation. TTR tetramer stabilization is based on the difference between the on-treatment FOI and the baseline FOI expressed as a percentage of the baseline FOI.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"94","spread":null},{"groupId":"OG001","value":"97","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94","spread":null},{"groupId":"OG001","value":"93","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Participants With Treatment-emergent Serious Adverse Events (SAEs)","description":"An Adverse Event (AE) was any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship. SAE: AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent/significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug, up to 30 days after last dose that were absent before treatment or that worsened relative to pretreatment state.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Participants With Treatment-emergent Adverse Events Greater Than or Equal to Grade 3","description":"AE=any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship. Grade 3 (Severe) events=unacceptable or intolerable events, significantly interrupting usual daily activity, require systemic drug therapy/other treatment. Grade 4 (Life-threatening) events caused participant to be in imminent danger of death. Grade 5 (Death) events=death related to an AE. Treatment-emergent events=between first dose of study drug and up to 30 days after last dose that were absent before treatment or that worsened relative to pretreatment state.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Participants With Clinically Significant Treatment-emergent Echocardiography (ECHO) Findings","description":"Clinically significant ECHO findings included: LV posterior wall thickness greater than or equal to (\\>=)13 mm, LV septal thickness \\>= 13 mm, right ventricular thickness \\>= 7 mm, ratio of peak mitral early diastolic and atrial contraction velocity (E/A ratio) \\>= 2, prime septal (E/E) \\>15, ejection fraction \\< 50 percent (%), E deceleration time \\<= 150 millisecond (ms), isovolumic relaxation time (IVRT) \\<= 70 ms, any valve thickening (\\> trace regurgitation in mitral, aortic, pulmonary, or tricuspid valves), abnormal respiratory variation of inferior vena cava, pericardial effusion.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Participants With Clinically Significant Treatment-emergent Electrocardiogram (ECG) Findings","description":"Clinically significant ECG findings included: corrected QT (QTc) \\> 450 ms, QTc \\>500 ms, change in QTc between 30 and 60 ms, change in QTc greater than or equal to 60 ms.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Participants With Clinically Significant Treatment-emergent Holter Monitor Findings","description":"Clinically significant Holter monitor findings included: atrial fibrillation/flutter, atrial tachycardia, non-sustained ventricular tachycardia (\\<30 beats), sustained ventricular tachycardia (\\>= 30 beats), sinus pause (RR \\>2.0 second, where RR=60/heart rate), ventricular premature contractions.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"21","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Participants Who Discontinued Due to Clinical or Laboratory Adverse Events","description":"An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":5,"n":44},"commonTop":["Urinary tract infection","Influenza","Nasopharyngitis","Thermal burn","Headache"]}}}